These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 5548781)

  • 1. Apparent failure of the two-compartment open model in describing the pharmacokinetics of intravenously injected hexobarbital in mice.
    Noordhoek J
    Arch Int Pharmacodyn Ther; 1971 Feb; 189(2):388-9. PubMed ID: 5548781
    [No Abstract]   [Full Text] [Related]  

  • 2. [Circadian-induced change in the pharmacokinetic pattern exemplified on hexobarbital/Retrospective analysis of experimental data (author's transl)].
    Altmayer P; Lücker PW; Rindt W
    Arzneimittelforschung; 1979; 29(10):1633-5. PubMed ID: 583232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmocokinetics of hexobarbital in man after intravenous infusion.
    Breimer DD; Honhoff C; Zilly W; Richter E; van Rossum JM
    J Pharmacokinet Biopharm; 1975 Feb; 3(1):1-11. PubMed ID: 1127574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of the enantiomers of hexobarbital studied in the same intact rat and in the same isolated perfused rat liver.
    Breimer DD; van Rossum JM
    Eur J Pharmacol; 1974 May; 26(2):321-30. PubMed ID: 4853606
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics of hexobarbital in acute hepatitis and after apparent recovery.
    Breimer DD; Zilly W; Richter E
    Clin Pharmacol Ther; 1975 Oct; 18(4):433-40. PubMed ID: 1164825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hexobarbital pharmacokinetics in rats after ligation of the common bile duct.
    Drew R; Priestly BG; O'Reilly WJ
    J Pharmacol Exp Ther; 1977 Jun; 201(3):534-40. PubMed ID: 864592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of diphenylhydantoin on hexobarbital sleep time in mice and rats.
    Kemp JW; Tannhauser M; Swinyard EA
    Arch Int Pharmacodyn Ther; 1971 Sep; 193(1):37-47. PubMed ID: 5111324
    [No Abstract]   [Full Text] [Related]  

  • 8. Stereoselective metabolism of the enantiomers of hexobarbital.
    Furner RL; McCarthy JS; Stitzel RE; Anders MW
    J Pharmacol Exp Ther; 1969 Oct; 169(2):153-8. PubMed ID: 5824599
    [No Abstract]   [Full Text] [Related]  

  • 9. [Half-life of hexobarbital and zoxazolamine in rodents. 2-In the rat].
    Buchel L; Absil J; Murawsky M
    C R Seances Soc Biol Fil; 1974; 168(2-3):265-70. PubMed ID: 4282286
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics of hexobarbital, sulphadimidine and chloramphencoliin neonatal and young pigs.
    Svendsen O
    Acta Vet Scand; 1976; 17(1):1-14. PubMed ID: 1266681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and dose-sleeping time lines of hexobarbital in mice.
    Noordhoek J
    Eur J Pharmacol; 1968 Jun; 3(3):242-50. PubMed ID: 5673637
    [No Abstract]   [Full Text] [Related]  

  • 12. Studies on some possible mechanisms of potentiation of hexobarbital hypnosis by pilocarpine, muscarine and arecoline.
    Tsujimoto A; Doi T; Ikeda M; Nishikawa T
    Arch Int Pharmacodyn Ther; 1974 Dec; 212(2):264-73. PubMed ID: 4447408
    [No Abstract]   [Full Text] [Related]  

  • 13. [Toxicity, narcotic effect, blood level after awakening, elimination from the blood and biotransformation of hexobarbital in rats of different ages after induction with barbital and carbon tetrachloride poisoning].
    Klinger W
    Arch Int Pharmacodyn Ther; 1970 Mar; 184(1):5-18. PubMed ID: 5448769
    [No Abstract]   [Full Text] [Related]  

  • 14. Hexobarbital action in rats with flavonoid-deficiency.
    Endell W; Seidel G
    Experientia; 1976 Sep; 32(9):1189-90. PubMed ID: 971760
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of drug metabolism. 3. Inhibition of hexobarbital metabolism in the intact rat and in the isolated perfused liver by 2-diethylaminoethyl 2,2-diphenylvalerate HC1 (SKF 525-A) and its N-deethylated derivatives.
    Stitzel RE; Anders MW; Mannering GJ
    Mol Pharmacol; 1966 Jul; 2(4):335-40. PubMed ID: 5968073
    [No Abstract]   [Full Text] [Related]  

  • 16. Disposition of hexobarbital: 15 years of an intriguing model substrate.
    van der Graaff M; Vermeulen NP; Breimer DD
    Drug Metab Rev; 1988; 19(2):109-64. PubMed ID: 3069420
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibition of hexobarbital metabolism by pyridyl derivatives.
    Varga F; Hankovszky OH; Hideg K; Fischer E; Szily T
    Acta Physiol Acad Sci Hung; 1973; 44(3-4):235-45. PubMed ID: 4807136
    [No Abstract]   [Full Text] [Related]  

  • 18. Influence of adrenal dysfunction on activity and pharmacokinetics of some neutropic drugs. II. Influence of chronic premedication with dexamethasone on pharmacodynamic activity and pharmacokinetics of drugs.
    Cenajek D; Szczawinńska K
    Arch Immunol Ther Exp (Warsz); 1975; 23(6):825-30. PubMed ID: 1220634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of pyralgin on pharmacodynamics and kinetics of hexobarbital].
    Mazurek K; Chodera A
    Acta Pol Pharm; 1981; 38(3):363-8. PubMed ID: 7315472
    [No Abstract]   [Full Text] [Related]  

  • 20. Interactions between 1,2--propanediol (propylene glycol) and hexobarbital.
    Osterlind A; Akesson A; Wahlström G
    Acta Pharmacol Toxicol (Copenh); 1979 Sep; 45(3):245-8. PubMed ID: 506748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.